This site uses cookies to ensure the best viewing experience for our readers.
Singapore’s VisVires Backs Israeli Shrimp-Health Startup ViAqua

Brief

Singapore’s VisVires Backs Israeli Shrimp-Health Startup ViAqua

ViAqua’s first product prevents and treats several ailments in shrimp, including white spot syndrome virus

Tofi Stoler | 13:33  13.12.2018
Singapore-based VisVires New Protein Master Fund Pte. Ltd. (VVNP), the food and feed investments division of VisVires Capital Asia Pte. Ltd. has invested in Israel-based medical aquafarming startup ViAqua Therapeutics Ltd., VVNP announced Wednesday. The financial terms of the investment were not disclosed.

Founded in 2014 and based in the Galilee, ViAqua develops a particle-based method for orally administering antiviral medication to shrimp. ViAqua’s first product, expected to go on the market in the next few months, prevents and treats several ailments including white spot syndrome virus, a highly contagious and deadly virus. Previous investors in ViAqua include Dutch animal feed company Nutreco NV, Singapore-listed, Israel-based venture firm Trendlines Group Ltd., and Israeli research university Technion Israel Institute of Technology.

Shrimp (illustration). Photo: Shutterstock Shrimp (illustration). Photo: Shutterstock Shrimp (illustration). Photo: Shutterstock

share on facebook share on twitter share on linkedin share on whatsapp share on mail

TAGS